BTIG analyst Justin Zelin reiterated a Buy rating on CASI Pharmaceuticals (CASI – Research Report) yesterday and set a price target of $10.00. The company’s shares closed yesterday at $1.95.
According to TipRanks, Zelin is a 2-star analyst with an average return of 0.2% and a 45.87% success rate. Zelin covers the Healthcare sector, focusing on stocks such as Poseida Therapeutics, MEI Pharma, and Adicet Bio.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for CASI Pharmaceuticals with a $10.00 average price target, a 412.82% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $10.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $10.51 and a one-year low of $1.81. Currently, CASI Pharmaceuticals has an average volume of 66.47K.
Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CASI in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong and Macau. Its products include ZEVALIN, EVOMELA and MARQIBO. CASI Pharmaceuticals was founded in 1991 and is headquartered in Rockville, MD.